SCHEMBL29405461

SCHEMBL29405461

COC(=O)c1ccc2c(c1)C(C)N(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
UCHL1 P09936 1/20 0.42
USP30 Q70CQ3 1/20 0.42
ESR2 Q92731 1/20 0.41
NPC1 O15118 3/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 2/20 0.41
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 2/20 0.40
KMT2A Q03164 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
XIAP P98170 1/20 0.39
BIRC2 Q13490 1/20 0.39
GHSR Q92847 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21470623 0.83 ESR2 (0.56) NR1H2SMN1; SMN2ESR2NPC1POLB
SCHEMBL21470624 0.83 ESR2 (0.56) NR1H2SMN1; SMN2ESR2NPC1POLB
SCHEMBL30710500 0.83 TRPM8 (0.41) NR1H2UCHL1USP30MAPK1KMT2A
SCHEMBL30710404 0.83 LMNA (0.42) NR1H2UCHL1USP30ESR2HDAC1
SCHEMBL30710250 0.83 LMNA (0.42) NR1H2UCHL1USP30ESR2HDAC1
SCHEMBL24528815 0.82 NR1H2 (0.45) NR1H2SMN1; SMN2UCHL1USP30ESR2
SCHEMBL21235427 0.82 ESR2 (0.46) NR1H2SMN1; SMN2USP30ESR2NPC1
SCHEMBL30878523 0.82 NR1H2 (0.45) NR1H2SMN1; SMN2UCHL1USP30ESR2
SCHEMBL18995111 0.82 ESR2 (0.46) NR1H2SMN1; SMN2USP30ESR2NPC1
SCHEMBL3353443 0.82 MAPK1 (0.43) NR1H2SMN1; SMN2UCHL1USP30POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114206852-A Plasma kallikrein inhibitors 卡尔维斯塔制药有限公司 2022-03-18 CN disclosed